Clinical trials: Advanced Pancreatic Carcinoma
Metastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma
Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
This phase I trial studies the side effects and best way to give personalized peptide vaccine in patients with pancreatic or colorectal cancer that has spread to other places in the body and usually cannot be cured or controlled…
- Conditions
- Metastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7
- Trial name
- NCT02600949
- Testing
- Imiquimod, Pembrolizumab, Sotigalimab
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumor Cancer
A Study of MC001 in Patients With Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) and Other Folate Receptor Alpha (FRα)-Expressing Solid Tumors
The purpose of this First-in-Human, Phase 1 study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary antitumor activity of MC001 in adults with advanced or…
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumor Cancer, Metastatic Pancreatic Cancer, Metastatic Solid Tumors
- Trial name
- NCT07909356
- Testing
- MC001
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Medicovestor, Inc
Metastatic Pancreatic Cancer
Gemcitabine (GFF) in Patients With Pancreatic Cancer
The purpose of this study is to examine the efficacy and safety of the drug combination GFF in patients with advanced pancreatic cancer (APC).
- Trial name
- GFF (NCT00919282)
- Testing
- gemcitabine, folinic acid, 5-FU
- Where
- Germany
- Volunteers
- 78 people
- Sponsor
- CONKO-Studiengruppe
Pancreatic Cancer
Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer
The purpose of the study is to determine the optimal safe and tolerable dose of gemcitabine in combination with once daily or twice daily dose of PTK/ZK in patients with unresectable pancreatic cancer.
- Trial name
- NCT00185588
- Testing
- Vatalanib, Gemcitabine
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- George Albert Fisher
Pancreatic Adenocarcinoma
Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE)
Pancreatic cancer is difficult to treat, and even in a situation where an operation can be performed to remove the cancer, the disease can unfortunately come back soon afterwards.
- Trial name
- PRICKLE (NCT02124369)
- Testing
- Abraxane, Gemcitabine
- Where
- United Kingdom
- Volunteers
- 9 people
- Sponsor
- CCTU- Cancer Theme
Pancreatic Adenocarcinoma, Homologous Recombination Deficiency
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency
The purpose of this study is to evaluate the efficacy of cisplatin based regimen to patients with advanced pancreatic cancer and homologous recombination deficiency.
- Trial name
- PTCA199-6 (NCT06095141)
- Testing
- Cisplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Advanced Pancreatic Adenocarcinoma
Peptide Nanovaccine (ONVAX-01) Plus Anti-PD-1 Antibody and Chemotherapy in Advanced Pancreatic Cancer
The goal of this clinical trial is to evaluate the safety and preliminary effectiveness of a new combination therapy in patients with advanced pancreatic cancer. The main questions it aims to answer are: 1.
- Trial name
- NCT07637786
- Testing
- ONVAX-01 plus Anti-PD-1 and Chemotherapy
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Sichuan University
Breast Cancer, Colorectal Cancer
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
RATIONALE: Bortezomib may stop the growth of solid tumors by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer
- Trial name
- NCT00620295
- Testing
- bortezomib, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Colorectal Cancer, Endometrial Cancer
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
RATIONALE: Vaccines made from a peptide may make the body build an immune response to kill tumor cells. Combining vaccine therapy with interleukin-2 and/or sargramostim may be a more effective treatment for solid tumors.
- Conditions
- Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Liver Cancer
- Trial name
- NCT00019331
- Testing
- aldesleukin, ras peptide cancer vaccine, sargramostim
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Pancreatic Ductal, Prognosis
Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures
The aim of this study is to assess the clinical value of 5 transcriptomic signatures prognostic of chemotherapeutic sensitivity to improve the Objective Response Rate (ORR) of first-line (L1).
- Trial name
- PACsign (NCT05475366)
- Testing
- Clinical value of 5 transcriptomic signatures to personalize the therapeutic decision for L1 in PDAC, Biomarkers of tumor signatures (translational studies)
- Where
- 7 sites in France
- Volunteers
- 79 people
- Sponsor
- Institut Curie
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors
This phase I trial is studying the side effects and best dose of gamma-secretase inhibitor RO4929097 when given together with gemcitabine hydrochloride in treating patients with advanced solid tumors.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT01145456
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, gemcitabine hydrochloride, pharmacological study
- Where
- 2 sites in Canada
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Pancreatic Carcinoma (LAPC)
Surgery Versus Stereotactic Ablative Radiotherapy for Patients With Locally Advanced Pancreatic Cancer With Favourable Biological Response Following Induction Chemotherapy
The primary objective of this study is to assess the added value of surgical exploration with intention for resection compared to MRI guided stereotactic ablative radiotherapy (SABR) in improving overall survival in patients with…
- Trial name
- PREOPANC-4 RCT (NCT07867873)
- Testing
- Pancreatic surgery, MRI guided stereotactic ablative radiotherapy
- Volunteers
- 230 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Advanced Solid Tumors
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors
PRI-724 is a new investigational drug being studied to treat subjects with cancer who have advanced solid tumors. PRI-724 is thought to work by blocking the Wnt signaling pathway that cancer cells need to grow and…
- Trial name
- NCT01302405
- Testing
- PRI-724
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Prism Pharma Co., Ltd.
Advanced Pancreatic Cancer
A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic Cancer
The purpose of this study is to evaluate the safety, tolerability, and efficacy of mitoxantrone hydrochloride liposome injection in patients with advanced pancreatic cancer.
- Trial name
- NCT05100329
- Testing
- Mitoxantrone Hydrochloride Liposome injection
- Volunteers
- 38 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Pancreatic Cancer
Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer
A phase I study to evaluate safety of gemcitabine with nab-paclitaxel and concurrent IMRT for locally advanced and borderline resectable pancreatic cancer.
- Trial name
- NCT02283372
- Testing
- nab-Paclitaxel, Gemcitabine, Intensity modulated radiation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Washington University School of Medicine
Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated…
- Conditions
- Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor
- Trial name
- NCT04924075
- Testing
- Belzutifan
- Where
- 84 sites in United States, Australia and 20 more
- Volunteers
- 355 people
- Sponsor
- Merck Sharp & Dohme LLC
Malignant Epithelial Mesothelioma, Adenocarcinoma of the Pancreas
Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment
This clinical trial will evaluate the safety and tolerability of CRS 207 an investigational product that is a weakened form (attenuated) of Listeria monocytogenes, a type of bacteria that is commonly found in the environment.
- Conditions
- Malignant Epithelial Mesothelioma, Adenocarcinoma of the Pancreas, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma of the Ovaries
- Trial name
- NCT00585845
- Testing
- CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin
- Where
- 4 sites in United States, Israel
- Volunteers
- 17 people
- Sponsor
- Anza Therapeutics, Inc.
Pancreatic Cancer
Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer
This phase II trial studies the side effects and how well irinotecan hydrochloride, oxaliplatin and cetuximab work in treating patients with unresectable or metastatic pancreatic cancer.
- Trial name
- NCT00871169
- Testing
- Irinotecan, oxaliplatin, and cetuximab
- Where
- 5 sites in United States
- Volunteers
- 61 people
- Sponsor
- New Mexico Cancer Research Alliance
Advanced Pancreatic Cancer
SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer
This is a prospective, multicenter, single arm clinical study. The main purpose of the study is to evaluate the clinical efficacy and safety of SBRT combined with Nimotuzumab and mono-chemotherapy in the treatment of locally…
- Trial name
- Nim-PC-28 (NCT06422156)
- Testing
- Stereotactic body radiation, Nimotuzumab, mono-chemotherapy
- Volunteers
- 73 people
- Sponsor
- Peking University Third Hospital
Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.
- Conditions
- Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- NCT07066657
- Testing
- MRG007, MRG007 and Bevacizumab
- Where
- 21 sites in United States, China
- Volunteers
- 572 people
- Sponsor
- ArriVent BioPharma, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.